Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-01
2007-05-01
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S248000, C514S249000, C514S259100, C514S291000, C514S300000, C540S460000, C540S461000, C544S236000, C544S278000, C544S281000, C544S282000, C544S349000, C546S086000, C546S113000
Reexamination Certificate
active
11255605
ABSTRACT:
The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.
REFERENCES:
patent: 5519016 (1996-05-01), Kimura et al.
patent: 5688791 (1997-11-01), Kimura et al.
patent: 2004/0039060 (2004-02-01), Kiyama et al.
patent: 2005/0119482 (2005-06-01), Egbertson et al.
patent: A 2 502281 (1990-07-01), None
patent: 6-116241 (1994-04-01), None
patent: 2000-502722 (2000-03-01), None
patent: 2002-155084 (2002-05-01), None
patent: 2002-293745 (2002-10-01), None
patent: WO 88/06588 (1988-09-01), None
patent: WO 98/08846 (1998-03-01), None
patent: WO 2001/95905 (2001-12-01), None
patent: WO 2001/96283 (2001-12-01), None
patent: WO 2002/22574 (2002-03-01), None
patent: WO 2002/30426 (2002-04-01), None
patent: WO 2002/30930 (2002-04-01), None
patent: WO 2002/30931 (2002-04-01), None
patent: WO 2002/36734 (2002-05-01), None
patent: WO 2002/055079 (2002-07-01), None
patent: WO 2003/016266 (2003-02-01), None
patent: WO 2003/016275 (2003-02-01), None
patent: WO 2003/031413 (2003-04-01), None
patent: WO 2003/035076 (2003-05-01), None
patent: WO 2003/035077 (2003-05-01), None
patent: WO 2003/047564 (2003-06-01), None
patent: WO 2004/024078 (2004-03-01), None
patent: WO2005/086700 (2005-09-01), None
patent: WO2005/087766 (2005-09-01), None
patent: WO2005/087767 (2005-09-01), None
patent: WO2005/087768 (2005-09-01), None
patent: WO2005/092099 (2005-10-01), None
patent: WO 2006/066414 (2006-06-01), None
Mekouar et al, “Stryrylquinoline Derivatives: A New Class of Potent HIV-1 Integrase Inhibitors That Block HIV-1 Replication in CEM Cells” Journal of Medicinal Chemistry, vol. 41(15), pp. 2546-2857 (1998).
Zouhiri et al, “Structure-Activity Relationships and Binding Mode of Styrylquinolines as Potent Inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture” Journal of Medicinal Chemistry, 43(8), pp. 1533-1540 (2000).
U.S. Appl. No. 60/349,775, filed Jun. 2005, Egbertson et al.
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. (Aug. 13, 2001).
Folia Pharmacologica Japonica, 118, pp. 131-134 (2001).
Breslow, D.S. et al., “The Synthesis of Certain 4-Aminoquinoline Derivatives” J. Am. Chem. Soc., 68, p. 1232 (1946).
Li et al., Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist (Tetrahedron Organic Chemistry Series, V. 20) (2000) Elsevier Science Ltd.
Lui et al., “Synthesis, Physicochemical Characterization and Biological Evaluation of 2-(1′-Hydroxyalkyl)-3-hydroxypyridin-4-one: Novel Iron Chelators with Enhanced pFe3+Values.” J. Med. Chem., 42, pp. 4818-4823 (1999).
Malleron et al., Handbook of Palladium-Catalysed Organic Reactions: Synthetic Aspects and Catalytic Cycles, (1997) Academic Press.
Mekouar et al., “Stryrylquinoline Derivatives: A New Class of Potent HIV-1 Integrase Inhibitors That Block HIV-1 Replication in CEM Cells” Journal of Medicinal Chemistry, vol. 41(15), pp. 2546-2587 (1998).
Micovic, I.V. et al., J. Chem. Soc., Perkin Trans. 16, p. 2041 (1996).
Zouhiri et al., “Structure-Activity Relationships and Binding Mode of Styrylquinolines as Potent Inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture” Journal of Medicinal Chemistry, vol. 43(8), pp. 1533-1540 (2000).
Adachi Kaoru
Isoshima Hirotaka
Katoh Susumu
Kiyonari Shinichi
Kobayashi Satoru
Finnegan Henderson Farabow Garrett & Dunner LLP
Japan Tobacco Inc.
Tucker Zachary C.
LandOfFree
Nitrogen-containing fused ring compound and use thereof as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen-containing fused ring compound and use thereof as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-containing fused ring compound and use thereof as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782319